Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive and Negative Solid Tumors

NCT03284723 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03284723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03284723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive and Negative Solid Tumors
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
November 1, 2017
Completion date
August 31, 2021
Enrollment
95 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms